

PARALLEL- (NGS) | SINGLE GENE SEQUENCING | PROGNOSTIC TESTING | LYMPHOMA AND PATHOGEN DIAGNOSTICS

BY FAX: 069 6301 5456

MOLEKULARPATHOLOGIE

Dr. Senckenberg, Institut für Pathologie
Universitätsklinikum Frankfurt koop.
Universitätsklinikum Frankfurt MVZ GmbH
(Wildlab), Prof. Dr. med. Peter J. Wild
Theodor-Stern-Kai 7, 60590 Frankfurt am Main

ORDERING PARTY (address, telephone number)

Date _____

Ordering Party _____

Case- | Block-No. _____

SPECIMEN DESCRIPTION

FFPE Blood Fresh

PAYER

Statutory health insurance, outpatient
Statutory health insurance, inpatient (in-house)
Statutory health insurance, inpatient (external)
Self-payer (GOÄ-invoice to patient following
declaration of cost coverage by insurer or patient)
§ 116b SGB V
ASV gastrointestinal tumors
ASV gynecological tumors

PATIENT LABEL

male female

Surname | First name _____

Date of birth _____

Address _____

Inpatient Outpatient
(At the time of this order)

Health insurance _____

IN OUTPATIENT CASES, PLEASE ATTACH REFERRAL SLIP.

CLINICAL INFORMATION | CLINICAL QUESTION | ADDITIONAL INFORMATION

SENDER (if different from ordering party) _____

SEND A COPY OF THE REPORT TO _____

SEND THE INVOICE TO _____

LOCATION | DATE

SIGNATURE

BARCODE (please leave this area blank)

INTERNAL M-NO.

THIS MOLECULAR PATHOLOGY TEST IS PERFORMED
AS PART OF THE „NATIONAL NETWORK FOR
GENOMIC MEDICINE (nNGM)“.

INVESTIGATIONS REQUESTED

IMMUNOHISTOCHEMICAL (IHC) MARKERS

PD-L1 ALK MLH1, MSH2, MSH6 and PMS2

PARALLEL SEQUENCING (NGS)

BRCA1/2 NGS Diagnostics

Gene-specific panel for **Liquid Biopsy** analyses

Lung DNA Panel (*EGFR, KRAS, BRAF, HER2* + other genes)

Archer® FusionPlex Lung RNA Panel (*ALK, ROS1, RET, MET, NTRK1* + other genes)

Archer® FusionPlex Sarcoma RNA Panel (*ALK, ROS1, EWSR1, FUS, SS18, NTRK2* + other genes)

Oncomine Comprehensive Assay v3 (**161 genes**, *BRCA1/2* and *BRCAness* genes + others, such as *NTRK1, NTRK2, NTRK3* and *POLR*). **Evidence of mutations, fusions and amplifications.**

<https://assets.thermofisher.com/TFS-Assets/LSG/brochures/oncomine-comprehensive-assay-v3-flyer.pdf>

Additional information on each respective gene set can be found on our website.

TruSight Oncology 500 Assay (500 genes, Illumina)

Comprehensive Genomic Profiling: Mutations, Fusions, Amplifications, MSI, TMB

Guided Reporting (Molecular Health)

Other _____ (Biomarkers common to all tumor types, please discuss with the MPC directly)

FASTTRACK ANALYSIS (SINGLE GENE ANALYSIS)

EGFR: Exon 18, 19, 20, 21

KRAS: Codon 12, 13, 61

BRAF: Codon 600

NRAS: Codon 12, 13, 61

LUNG- | THYROID CARCINOMA | COLORECTAL CARCINOMA | MALIGNANT MELANOMA | OTHER

BRAF: Exon 11 – Codon 464–469

Exon 15 – Codon 600

EGFR: Exon 18, 19, 20, 21

EGFR: p.T790M in resistant cases (Liquid Biopsy)

RAS: *KRAS* & *NRAS* Exon 2, 3, 4

– Codon 12, 13, 59, 61, 117, 146

NRAS: Exon 2, 3, 4

– Codon 12, 13, 59, 61, 117, 146

KRAS: Exon 2, 3 – Codon 12, 13, 61

Microsatellite instability (MSI)* - Length analysis fragment

* PATIENT CONSENT HAS BEEN DOCUMENTED (REQUIRED)

LYMPHOMA DIAGNOSTICS

Clonality analysis *TcR β*

Clonality analysis *TcR γ*

Clonality analysis *IGH*

RHOA: Exon 3 – Codon 17

t(14; 18) (*IGH/BCL2*)

MYD88: Exon 5

JAK2: Exon 14

MELANOMA

Oncomine Comprehensive Assay v3

BRAF *NRAS*

GYNECOLOGICAL CARCINOMAS | OTHER

Oncomine Comprehensive Assay v3

(161 genes including *BRCA1/2* and *BRCAness* genes, see above)

MLH1, MSH2, MSH6 and PMS2 (IHC)

Liquid Biopsy analysis (*ESR1, PIK3CA, PTEN, AKT1*)

Hormone receptors ER, PR (IHC)

HER2 (IHC) ○ AR (IHC)

HRD-Assay

UROLOGICAL CARCINOMAS | OTHER

Oncomine Comprehensive Assay v3

(161 genes including *BRCA1/2* and *BRCAness* genes, see above)

Proclarix (Prognosis assessment, NEW) (probability of

high-grade carcinoma, Gleason score ≥7)

PATHOGEN DIAGNOSTICS

Evidence of mycobacteria

typical (TBC-complex) and atypical mycobacteria

Evidence and subtyping of HPV

Evidence of fungi (candida, aspergillus and other fungi)